Profile data is unavailable for this security.
About the company
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
- Revenue in USD (TTM)159.11m
- Net income in USD-65.81m
- Incorporated2007
- Employees267.00
- LocationArdelyx Inc34175 Ardenwood BlvdFREMONT 94555-3653United StatesUSA
- Phone+1 (510) 745-7047
- Fax+1 (510) 745-0493
- Websitehttps://www.ardelyx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kura Oncology Inc | 0.00 | -168.09m | 1.69bn | 142.00 | -- | 3.34 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.69bn | 92.00 | -- | 3.16 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.72bn | 112.00 | -- | 3.51 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 1.78bn | 1.22k | -- | 1.66 | -- | 8.54 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Protagonist Therapeutics Inc | 314.95m | 162.11m | 1.80bn | 124.00 | 12.50 | 3.21 | 11.06 | 5.72 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Inhibrx Inc | 1.78m | -271.16m | 1.81bn | 166.00 | -- | 147.69 | -- | 1,017.41 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Novavax Inc | 996.61m | -398.71m | 1.83bn | 1.54k | -- | -- | -- | 1.83 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Ardelyx Inc | 159.11m | -65.81m | 1.83bn | 267.00 | -- | 12.11 | -- | 11.48 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Fusion Pharmaceuticals Inc | 2.04m | -104.28m | 1.83bn | 113.00 | -- | 7.55 | -- | 896.88 | -1.42 | -1.42 | 0.0279 | 2.85 | 0.0069 | -- | 45.84 | 18,053.10 | -35.33 | -35.45 | -37.76 | -38.55 | -- | -- | -5,111.57 | -7,206.24 | -- | -- | 0.1704 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
| Keros Therapeutics Inc | 234.00k | -160.30m | 1.89bn | 141.00 | -- | 4.15 | -- | 8,061.82 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Sana Biotechnology Inc | 0.00 | -308.61m | 1.93bn | 328.00 | -- | 5.15 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -43.21 | -38.99 | -48.50 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.95bn | 167.00 | 30.63 | 3.47 | 19.32 | 4.73 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.95bn | 383.00 | -- | 2.62 | -- | 66.31 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Data as of May 17 2024. Currency figures normalised to Ardelyx Inc's reporting currency: US Dollar USD
38.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 21.92m | 9.42% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 15.07m | 6.48% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 14.09m | 6.06% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 12.85m | 5.52% |
| Eventide Asset Management LLCas of 31 Mar 2024 | 6.81m | 2.93% |
| Geode Capital Management LLCas of 31 Mar 2024 | 5.21m | 2.24% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.78m | 1.63% |
| Macquarie Investment Management Business Trustas of 31 Mar 2024 | 3.69m | 1.58% |
| Voloridge Investment Management LLCas of 31 Mar 2024 | 3.30m | 1.42% |
| Two Sigma Investments LPas of 31 Mar 2024 | 2.56m | 1.10% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
